Processa Pharmaceuticals, Inc. Operating Income Loss

• Processa Pharmaceuticals, Inc. showed a decrease of -16.1% in Operating Income Loss from 2024 to 2025.
• This data is from Processa Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
• XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 10 years of available data (2016 to 2025), Processa Pharmaceuticals, Inc.'s Operating Income Loss has declined by 628.0%.
• Historical annual values: Fiscal year 2025: -$13.99 million | Fiscal year 2024: -$12.05 million | Fiscal year 2023: -$11.46 million | Fiscal year 2022: -$27.53 million | Fiscal year 2021: -$12.13 million | Fiscal year 2020: -$15.14 million | Fiscal year 2019: -$3.94 million | Fiscal year 2018: -$4.52 million | Fiscal year 2017: -$1.80 million | Fiscal year 2016: -$1.92 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026